chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 97.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19 pneumonia, Sepsis
Clinical narrative: 7/5/2023 - 7/12/2023 (7 days) admitted with Covid pneumonia as well as sepsis and the patient was treated with Remdesivir as well as decadron during the hospitalization 030M20A 2/15/2021 001A21A 3/15/2021 058H21A 12/7/2021
Age: 58.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dyspnoea
Clinical narrative: EW0198 7/21/2021 FC3180 8/11/2021 7/12/2023 - present (16 days) presents to the emergency department complaining of worsening shortness of breath x1 day
Age: 86.0
Sex: F
Vaccine: COVID19, COVID19, COVID19-2
Symptoms: Syncope
Clinical narrative: 7/14/2023 - 7/18/2023 (4 days) presented to emergency room with syncopal episode remdesivir IV/Decadron IV  013M20A 3/3/2021 035C21A 11/3/2021 AS7148B 9/14/2022
Age: 92.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19-2
Symptoms: Asthenia, Confusional state
Clinical narrative: 7/14/2023 - 7/22/2023 (8 days) Presented to the ED due to weakness, confusion of one day duration.  Admitted and started on iv rocephin /zithromax, ivf,  iv remdesivir and systemic steroids along with bronchodilators GL0446 11/18/2022 11/13/2021 FG3527 3/20/2021 ER8727 EN6198 2/27/2021
Age: 66.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dyspnoea
Clinical narrative: 7/15/2023 - 7/18/2023 (3 days) emergency department for shortness of breath rocephin and zithromycin - completed Remdesivir 039B21A 4/21/2021 027C21A 5/24/2021
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, Chronic respiratory failure, Respiratory failure
Clinical narrative: ACUTE RESPIRATORY FAILURE CHRONIC HYPOXEMIC RESPIRATORY FAILURE
Age: 76.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dyspnoea
Clinical narrative: EP7534 3/18/2021 EP7533 4/8/2021 7/15/2023 - 7/23/2023 (8 days) worsening shortness of breath s/p 5 days of remdesivir, continued on Decadron, bronchodilators
Age: 66.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Pain, Pyrexia
Clinical narrative: EN5318 2/4/2021 EN6203 2/25/2021 FC3180 8/20/2021 FM7553 6/10/2022 Pfizer Bivalent GJ2524 10/31/2022 7/22/2023 - 7/24/2023 (2 days)  102.2 fevers and generalized body aches, was brought into emergency room for evaluation of possible encephalopathy and dysarthria on 07/22/2023
Age: 30.0
Sex: M
Vaccine: TD
Symptoms: Arthralgia
Clinical narrative: Ongoing shoulder pain
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure
Clinical narrative: ACUTE RESPIRATORY FAILURE ACUTE HYPOXEMIC RESPIRATORY FAILURE
Age: 84.0
Sex: M
Vaccine: COVID19
Symptoms: Bell's palsy, Facial paresis, Symptom recurrence
Clinical narrative: LEFT BELLS PALSY RIGHT FACIAL MUSCLE WEAKNESS 7/23/2022  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Age: 20.0
Sex: F
Vaccine: MENB
Symptoms: Rash, Urticaria
Clinical narrative: injection given approx 230pm  on 8/17/23.   pt states reaction started a little more than an hour later  around 4pm.   pt did not notify pharmacy until next day at approx 930am on 8/18/23.   reaction manifested as skin rash on chest, arms and body with hives like response.  Recommended diphenydramine 25mg  1 cap every 6 hours (gave pt 4  capsules  to take with them for treatment on 8/18/23 at 930am)  instructed pt to contact md if hives do not improve or worsens.
Age: 73.0
Sex: F
Vaccine: COVID19-2, FLU4, PNC20, VARZOS
Symptoms: Expired product administered, No adverse event
Clinical narrative: Given Pfizer COVID Vaccine after BUD of 10 weeks. No other adverse events reported.
Sex: U
Vaccine: COVID19
Symptoms: Chronic fatigue syndrome, Fibromyalgia, Mast cell activation syndrome, Post vaccination syndrome
Clinical narrative: Mast cell activation syndrome; Myalgic encephalomyelitis/Chronic fatigue syndrome; Fibromyalgia; Post Vaccine Syndrome; This spontaneous case was reported by a patient and describes the occurrence of MAST CELL ACTIVATION SYNDROME (Mast cell activation syndrome) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 17-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Feb-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced POST VACCINATION SYNDROME (Post Vaccine Syndrome). On an unknown date, the patient experienced MAST CELL ACTIVATION SYNDROME (Mast cell activation syndrome) (seriousness criterion medically significant), CHRONIC FATIGUE SYNDROME (Myalgic encephalomyelitis/Chronic fatigue syndrome) and FIBROMYALGIA (Fibromyalgia). At the time of the report, MAST CELL ACTIVATION SYNDROME (Mast cell activation syndrome), CHRONIC FATIGUE SYNDROME (Myalgic encephalomyelitis/Chronic fatigue syndrome) and FIBROMYALGIA (Fibromyalgia) outcome was unknown and POST VACCINATION SYNDROME (Post Vaccine Syndrome) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Patient had been suffering from Post-Vac Syndrome and had been unable to work since 21 Feb 2022. Concomitant medications were not reported.  No treatment information was provided by the reporter.  Company comment: This spontaneous case concerns a patient of unknown age and gender, with no medical history information reported, who experienced the unexpected serious (medically significant) event of Mast cell activation syndrome and non serious AESI of Myalgic encephalomyelitis/chronic fatigue syndrome, Fibromyalgia and non serious event of post vaccination syndrome. The event of post vaccination syndrome occurred after the first dose of mRNA-1273, while the rest of the events occurred on a later date. As reported, patient had post vaccination syndrome following first dose and had diagnoses of Myalgic encephalomyelitis/chronic fatigue syndrome, Fibromyalgia and mast cell vaccination syndrome made so far and the patient was unable to work since 9 months after first dose. No further information was provided regarding the events including any diagnostic tests conducted confirming the diagnoses or clinical course of events. The benefit-risk relationship of mRNA-1273 is not affected by this report.
Age: 85.0
Sex: F
Vaccine: COVID19
Symptoms: Obstructive sleep apnoea syndrome
Clinical narrative: OBSTRUCTIVE SLEEP APNEA
Age: 33.0
Sex: M
Vaccine: COVID19-2
Symptoms: Back pain
Clinical narrative: Severe back pain
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Obstructive sleep apnoea syndrome
Clinical narrative: ADULT OBSTRUCTIVE SLEEP APNEA
Age: 11.0
Sex: F
Vaccine: MNQ
Symptoms: No adverse event, Product preparation issue
Clinical narrative: The vaccine comes with to components a powder and liquid that should be mixed. The MA that admistered vaccine did not mix the two. Pt was only given the liquid portion of the vaccine. No reactions noted per the administering ma. No treatment was needed before pt leaving clinic.
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoxia, Pulmonary embolism, Pulmonary infarction
Clinical narrative: PULMONARY EMBOLISM W INFARCTION, UNSPECIFIED HYPOXIA
Age: 15.0
Sex: M
Vaccine: HEPA, HPV9, MNQ, TDAP, VARCEL
Symptoms: Dizziness
Clinical narrative: 10-15 minutes after vaccination, patient felt lightheaded and slumped to the floor.  Did not have complete loss of consciousness.
Age: 46.0
Sex: F
Vaccine: TDAP
Symptoms: Injection site induration, Injection site swelling
Clinical narrative: swollen, hard bump around the injection site
Age: 15.0
Sex: F
Vaccine: IPV, MMR, TDAP, VARCEL
Symptoms: Blister, Pruritus, Scab, Scar
Clinical narrative: Patient received MMR, IPV, Tdap and Varicella Vaccines on 8/21/2023.     Mother reported that around August 2, 2023 around 9:00AM , 12 days after being vaccinated her daughter began to experience itching, and later noticed fluid filled vesicles to her upper torso that looked like she had chicken pox.  No other symptoms  reported by mother. Upon further assessment today, noted one dry crusty scar to mid upper umbilical region. No rashes, scars or other fluid  filled vesicles noted.
Age: 1.25
Sex: F
Vaccine: HEPA, HIBV
Symptoms: Discomfort, Irritability, Rash, Urticaria
Clinical narrative: 2 days after immunization pt developed an urticarial rash on her right thigh, trunk, and face. She was otherwise well. Overnight, she was fussy and seemed uncomfortable, so parents gave a dose of Zyrtec. The following day the urticaria were resolve.
Age: 58.0
Sex: F
Vaccine: PNC20
Symptoms: Erythema, Induration, Local reaction
Clinical narrative: local reaction with 9cm x 5 cm area of induration and erythema
Age: 24.0
Sex: F
Vaccine: FLU4, UNK
Symptoms: Malaise, Vaccination site erythema, Vaccination site mass, Vaccination site warmth
Clinical narrative: Patient reported Friday 08/11/2023 that after the vaccine, the vaccination site got red, feels hot and has a bump. She reported that day because the bump got bigger and Thursday she felt sick. Advised her to see a doctor if she feels she have to. I followed up the following Monday and she said the bump subsided and does not feel hot anymore but it's still red. She didn't go to the doctor.
Age: 53.0
Sex: M
Vaccine: VARZOS
Symptoms: Arthralgia, Pain
Clinical narrative: Body ache, injection site swelling, joint ache
Age: 13.0
Sex: F
Vaccine: HPV9
Symptoms: Syncope
Clinical narrative: syncopal episode following injection - return to baseline after laying down with feet up and having juice/snack.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Angina pectoris
Clinical narrative: STABLE ANGINA
Age: 67.0
Sex: M
Vaccine: COVID19-2
Symptoms: Chills, Hyperhidrosis, Pyrexia
Clinical narrative: fever, chills, sweats
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Ischaemic stroke
Clinical narrative: ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY
Age: 75.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Blood lactic acid increased, COVID-19, Dyspnoea, SARS-CoV-2 test positive
Clinical narrative: Covid 19+ Elevated lactic  Consult infectious disease for COVID-19 infection Patients wife reports patient was experiencing SOB but denies any other signs of infection, no fevers Check patient inflammatory markers, C-reactive protein, CPK, D-dimer, ferritin, LDH Start decadron Check Liver function to evaluate if patient is candidate for remdesivir (spoke with patient's wife and she gave consent to remdesivir if patient qualifies) Rule out underlying infectious process, start IV antibiotics Check urine, sputum, and blood cultures Check procalcitonin level
Age: 1.08
Sex: M
Vaccine: PNC15
Symptoms: Febrile convulsion
Clinical narrative: Febrile seizure occurring x 3-5 minutes, treated at UC and then transferred to ED.  Given intranasal versed x1. Discharged home same day.
Age: 4.0
Sex: F
Vaccine: DTAPHEPBIP
Symptoms: Extra dose administered, No adverse event
Clinical narrative: Patient was given the Pediarix vaccine (DTap-HepB-IPV) but she needed the Kinrix vaccine (DTap-IPV). So she did recieve an extra Hep-B vaccine. Patient did not have any adverse reactions or problems and mom was informed.
Age: 88.0
Sex: F
Vaccine: COVID19
Symptoms: Hypotension, Symptom recurrence
Clinical narrative: HYPOTENSION 4/20/2022 & 7/31/2022  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Age: 39.0
Sex: F
Vaccine: HEP
Symptoms: Alopecia
Clinical narrative: Patient called 08/18/23 complaining of hair loss that started approximately 2 days after vaccination on 08/03/23.  There has been no treatment at this time.  She has an appointment soon with PCP.
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Respiratory failure
Clinical narrative: ACUTE RESPIRATORY FAILURE RESPIRATORY FAILURE, UNSPECIFIED ACUITY
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: PATIENT RECEIVED VACCINE AFTER BUD
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Atelectasis, COVID-19, Chest X-ray abnormal, Chronic obstructive pulmonary disease, Condition aggravated
Clinical narrative: COPD exacerbation secondary to COVID-19 infection, suspected bacterial Community-acquired pneumonia:  Chest x-ray with left basilar subsegmental atelectasis Currently afebrile, no leukocytosis, WBC WNL Completed course of Rocephin and azithromycin to cover possible superimposed bacterial infection
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Pneumonia, Pneumonia bacterial, White blood cell count normal
Clinical narrative: COPD exacerbation secondary to COVID-19 infection, suspected bacterial Community-acquired pneumonia:  Chest x-ray with left basilar subsegmental atelectasis Currently afebrile, no leukocytosis, WBC WNL Completed course of Rocephin and azithromycin to cover possible superimposed bacterial infection
Age: 86.0
Sex: M
Vaccine: COVID19
Symptoms: Acute myocardial infarction
Clinical narrative: ACUTE NON ST ELEVATION MI
Age: 69.0
Sex: F
Vaccine: VARZOS
Symptoms: Arthralgia, Myalgia, Pain
Clinical narrative: SE started 2 weeks after the vaccine: radiating pain throughout the body with muscle and joint pain
Age: 84.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19
Clinical narrative: Regarding COVID-19 infection supportive care at this point requiring  No oxygen
Age: 2.0
Sex: F
Vaccine: COVID19-2
Symptoms: Interchange of vaccine products, No adverse event
Clinical narrative: Patient received a Moderna BvlntBstr dose on 06/21/2023 (Lot AS7185B) for their first dose in the COVID-19 vaccine series. They were supposed to receive a second dose of Moderna BvlntBstr for the second dose of COVID-19 vaccine but they received a dose of Pfizer BvlntBstr 6M-4Y instead. Patient has no adverse symptoms from this vaccine administration to our knowledge. It was just an error in vaccine type administered.
Age: 77.0
Sex: M
Vaccine: COVID19, COVID19, UNK
Symptoms: COVID-19 pneumonia, Intensive care
Clinical narrative: Covid 19 pneumonia.  The patient initially required ICU admission and iv pressors and high flow oxygen.  The patient was later downgraded from the ICU and transferred to another unit.  The patient was recommended to transition to SNF for further rehab.  The patient completed his remdesivir and would continue decadron for a total of 10 days.
Age: 83.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19-2
Symptoms: Asthma, Wheezing
Clinical narrative: Patient without oxygen requirement at present. No indications for COVID-19 specific therapy.  Saturating well on room air with SpO2 greater than 94%. Treated with Decadron 6 mg daily for mild wheezing/asthma, currently resolved
Sex: M
Vaccine: HEP
Symptoms: Extra dose administered
Clinical narrative: Infant was delivered prematurely but was big enough that we would give hepatitis B.  There was an order placed for it to be given at birth.  Usually when a baby is on CPAP, it is delayed.  A second order set was placed when the infant was in the special care unit for hepatitis B vaccine to be given at 48 hours.  It was not recognized by pharmacy or nursing that the infant already had a dose, and he received a second dose.  It was not discovered until the infant went to the pediatrician's office.  She saw that 2 doses had been given.  The hospital pediatrician will call the family to let them know about the second dose.  The second dose was given 8/4/23 at 1059. All the vaccine information was the same as the first dose.
Age: 12.0
Sex: M
Vaccine: HPV9, MNQ, TDAP
Symptoms: Presyncope
Clinical narrative: Patient had a vasovagal reaction 15 minutes post vaccinations. Patient recovered okay and was able to leave building with mother on his own.
Age: 64.0
Sex: F
Vaccine: RSV
Symptoms: Injection site erythema, Injection site mass, Injection site pain
Clinical narrative: a couple of days later I started hurting at that spot (injection site) with redness and would not go away, I contacted my doctor and went in to them it is about 7 inches in swelling with 2 inches of redness, doctor said it did not look like an infections but to call VAERS. I have noticed some of the redness and swelling had gone down but still have that hard lump under the skin.
Age: 83.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: Moderna COVID 19 Bivalent ordered by provider and administered by Medical Assistant. Patient waited the 15-20min triage time for evaluation and reported no symptoms and well to return home. After administration it was brought to our attention that vaccine that was given was expired as of August 8th, 2023. Patient informed and counseled by PCP, Dr. before leaving clinic.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Facial paresis, Reversible ischaemic neurological deficit
Clinical narrative: REVERSIBLE ISCHEMIC NEUROLOGIC DEFICIT SYNDROME LEFT FACIAL MUSCLE WEAKNESS
Age: 95.0
Sex: M
Vaccine: COVID19
Symptoms: Breakthrough COVID-19
Clinical narrative: Covid-19 Breakthrough infection
Age: 48.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: The patient was given an expired dose of COVID-19 vaccine. The vaccine expired on 8/09/23. Despite efforts to remove our expired vaccine from stock, a few doses were coded incorrectly and remained within our vaccine dispensing system.
Age: 73.0
Sex: F
Vaccine: COVID19-2
Symptoms: Extra dose administered
Clinical narrative: Given third dose of omicron bivalent booster. No reaction for 15 minutes.
Age: 86.0
Sex: F
Vaccine: COVID19
Symptoms: Breakthrough COVID-19
Clinical narrative: Covid-19 Breakthrough Infecton
Age: 74.0
Sex: M
Vaccine: COVID19-2
Symptoms: Extra dose administered
Clinical narrative: Given 3rd omicron bivalent booster
Age: 68.0
Sex: F
Vaccine: COVID19-2
Symptoms: Extra dose administered
Clinical narrative: Patient administered 3rd dose of omicron bivalent booster.
Sex: U
Vaccine: COVID19-2
Symptoms: Incorrect dose administered, No adverse event
Clinical narrative: 3 pediatric patients (between the ages of 6 months - 5 years) could have received their first or 2nd dose from the Dark Pink cap instead of Blue cap at their facility, essentially receiving a lower than authorized dose.; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of INCORRECT DOSE ADMINISTERED (3 pediatric patients (between the ages of 6 months - 5 years) could have received their first or 2nd dose from the Dark Pink cap instead of Blue cap at their facility, essentially receiving a lower than authorized dose.) and NO ADVERSE EVENT (No adverse event) in a patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced INCORRECT DOSE ADMINISTERED (3 pediatric patients (between the ages of 6 months - 5 years) could have received their first or 2nd dose from the Dark Pink cap instead of Blue cap at their facility, essentially receiving a lower than authorized dose.) and NO ADVERSE EVENT (No adverse event). At the time of the report, INCORRECT DOSE ADMINISTERED (3 pediatric patients (between the ages of 6 months - 5 years) could have received their first or 2nd dose from the Dark Pink cap instead of Blue cap at their facility, essentially receiving a lower than authorized dose.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for INCORRECT DOSE ADMINISTERED (3 pediatric patients (between the ages of 6 months - 5 years) could have received their first or 2nd dose from the Dark Pink cap instead of Blue cap at their facility, essentially receiving a lower than authorized dose.).    Patient age was reported as between the ages of 6 months to 5 years. Concomitant medication details not reported by the reporter. Treatment details was not reported by the reporter. This case contains information about 3rd patient out of 3.   This case was linked to US-MODERNATX, INC.-MOD-2023-736989 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-736989:Master case (Patient 1)
Age: 2.0
Sex: M
Vaccine: DTAP, HIBV
Symptoms: Gait disturbance, Injection site bruising, Injection site induration, Injection site pruritus, Injection site reaction
Clinical narrative: 08/02/23 Pt. was crying more that evening. Mom felt that area was sore and gave ibuprofen. 08/03 the left thigh was red, swollen, warm to touch and felt hard. Guesstimating 3 inches wide and 2 inches long. Mother again gave ibuprofen that morning and the night. 08/04 Mom thought the area looked a little better, tried putting ice to the area.  She felt like the red was starting to streak and go around the thigh.  Pt.'s thigh is swollen and is not walking well. 08/04 Mother took pt. to a PCP.  PCP ordered 3 days worth of steroids.  08/12/23 When I talked with Mom, she said pt. was a lot better.  The steroids really helped a lot. No hardness, no redness really just the area is bruised looking with small little bumps and she has seen him scratching the area. 08/18/23 talked to mom. Child is acting fine.  He has since seen a pediatrician for a 2 y/o well child visit.  This doctor did not feel like it was an allergic reaction but more of a strong local reaction.
Age: 2.0
Sex: M
Vaccine: DTAP, HIBV
Symptoms: Injection site swelling, Injection site warmth
Clinical narrative: 08/02/23 Pt. was crying more that evening. Mom felt that area was sore and gave ibuprofen. 08/03 the left thigh was red, swollen, warm to touch and felt hard. Guesstimating 3 inches wide and 2 inches long. Mother again gave ibuprofen that morning and the night. 08/04 Mom thought the area looked a little better, tried putting ice to the area.  She felt like the red was starting to streak and go around the thigh.  Pt.'s thigh is swollen and is not walking well. 08/04 Mother took pt. to a PCP.  PCP ordered 3 days worth of steroids.  08/12/23 When I talked with Mom, she said pt. was a lot better.  The steroids really helped a lot. No hardness, no redness really just the area is bruised looking with small little bumps and she has seen him scratching the area. 08/18/23 talked to mom. Child is acting fine.  He has since seen a pediatrician for a 2 y/o well child visit.  This doctor did not feel like it was an allergic reaction but more of a strong local reaction.
Age: 3.0
Sex: F
Vaccine: VARCEL
Symptoms: Cold sweat, Cough, Crying, Eye movement disorder, Hypotonia
Clinical narrative: Did excellent with administration, used ice on the site prior, watched vaccine being given, no crying, not upset. Several minutes following as mom was getting up to leave with her, the patient started coughing/gagging, went limp, eyes rolled back and collapsed on mom for 5-10 seconds, remained breathing throughout but unresponsive.  After about 5-10 seconds began coughing again a little, crying and but became responsive to her name with visual contact.  Was able to answer questions and alert within a minute or so.  Following was a little clammy, and cuddly with mom but smiling and fully oriented.
Age: 3.0
Sex: F
Vaccine: VARCEL
Symptoms: Retching, Syncope, Unresponsive to stimuli
Clinical narrative: Did excellent with administration, used ice on the site prior, watched vaccine being given, no crying, not upset. Several minutes following as mom was getting up to leave with her, the patient started coughing/gagging, went limp, eyes rolled back and collapsed on mom for 5-10 seconds, remained breathing throughout but unresponsive.  After about 5-10 seconds began coughing again a little, crying and but became responsive to her name with visual contact.  Was able to answer questions and alert within a minute or so.  Following was a little clammy, and cuddly with mom but smiling and fully oriented.
Age: 18.0
Sex: F
Vaccine: MENB
Symptoms: Injection site pain, Injection site swelling
Clinical narrative: localized swelling and soreness to the left deltoid muscle.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; Vaccine was administered post expiration date 13-JUL-2022; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine was administered post expiration date 13-JUL-2022) and NO ADVERSE EVENT (No adverse event) in a 51-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004M21A) for COVID-19 prophylaxis.     Patient did not describe any medical history or conditions.     On 21-Jul-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 21-Jul-2022, after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine was administered post expiration date 13-JUL-2022). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine was administered post expiration date 13-JUL-2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Vaccine was administered post expiration date 13-JUL-2022).    It was unknown if the patient receive any other vaccines in the 4 weeks prior to COVID-19 vaccine. Previous doses were not reported.  No concomitant medication was reported.   The expiration date was reported as 13-JUL-2022. Caller wanted to know what the stability of the vaccine after 13-Jun-2022.  No treatment information was reported.  This case contains information for patient 2 out of 4.   This case was linked to US-MODERNATX, INC.-MOD-2023-737010 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-737010:Master case, Patient 1
Sex: M
Vaccine: COVID19-2
Symptoms: Cardiac arrest, Incontinence, Pulmonary embolism
Clinical narrative: Cardiac arrest; Blood clot in the lung; Incontinence; This spontaneous case was reported by a patient family member or friend and describes the occurrence of CARDIAC ARREST (Cardiac arrest) and PULMONARY EMBOLISM (Blood clot in the lung) in a male patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Concomitant products included HEPARIN for Thrombosis prophylaxis.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced CARDIAC ARREST (Cardiac arrest) (seriousness criteria death and medically significant), PULMONARY EMBOLISM (Blood clot in the lung) (seriousness criteria death and medically significant) and INCONTINENCE (Incontinence). The patient died on 19-Apr-2023. The reported cause of death was Cardiac arrest and blood clot in the lung. It is unknown if an autopsy was performed. At the time of death, INCONTINENCE (Incontinence) outcome was unknown.            On an unknown date, patient received Moderna COVID shots and boosters.   On an unknown date, patient went to hospital for incontinence and died on 19-Apr-2023 from cardiac arrest and blood clot in the lung.  Patient was getting heparin shots to prevent clots.  No treatment medication was provided. Company comment: This spontaneous case concerns a male patient of unknown age, with no medical history reported, who experienced unexpected serious (death, medically significant) events of cardiac arrest and pulmonary embolism which occurred after receiving a dose of mRNA-1273.222, which was the patient's unknown dose of COVID-19 vaccination schedule. Latency cannot be calculated due to vaccination date unknown. It was described that the patient went to hospital due to incontinence and died later due to pulmonary embolism and cardiac arrest. No further details regarding clinical course, any accompanying circumstances that could lead to fatality, concurrent diseases, concomitant medications and whether the patient was hospitalized due to incontinence are available in the report. Outcome of events was fatal at the time of the report. Additional information has been requested and report will be updated upon receipt of follow up information. The benefit-risk relationship of mRNA-1273.222 vaccine is not affected by this report.   This case was linked to US-MODERNATX, INC.-MOD-2023-737183 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-737183:Reporter's case; Reported Cause(s) of Death: Cardiac arrest; Blood clot in the lung
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Balance disorder
Clinical narrative: Loss of balance while walking, especially when turning; This spontaneous case was reported by a consumer and describes the occurrence of BALANCE DISORDER (Loss of balance while walking, especially when turning) in an 83-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030M20A) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) 1 dosage form. On an unknown date, the patient experienced BALANCE DISORDER (Loss of balance while walking, especially when turning). At the time of the report, BALANCE DISORDER (Loss of balance while walking, especially when turning) had not resolved.            No concomitant drug was reported.  It was unknown if the patient experienced any additional symptoms/events.  No treatment drug was reported.
Age: 68.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Vaccine was pulled from freezer 23-Jun-2023 and was stored in the refrigerator since. Pharmacist was unaware that vaccine can only be refrigerated for 30 days; No adverse event; Expired vaccine was administered; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine was administered), PRODUCT STORAGE ERROR (Vaccine was pulled from freezer 23-Jun-2023 and was stored in the refrigerator since. Pharmacist was unaware that vaccine can only be refrigerated for 30 days) and NO ADVERSE EVENT (No adverse event) in a 68-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7643E) for COVID-19 prophylaxis.     No Medical History information was reported.    On 03-Aug-2023, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 03-Aug-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine was administered). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine was pulled from freezer 23-Jun-2023 and was stored in the refrigerator since. Pharmacist was unaware that vaccine can only be refrigerated for 30 days) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine was administered), PRODUCT STORAGE ERROR (Vaccine was pulled from freezer 23-Jun-2023 and was stored in the refrigerator since. Pharmacist was unaware that vaccine can only be refrigerated for 30 days) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Expired vaccine was administered) and PRODUCT STORAGE ERROR (Vaccine was pulled from freezer 23-Jun-2023 and was stored in the refrigerator since. Pharmacist was unaware that vaccine can only be refrigerated for 30 days).    No concomitant medication was reported.  No treatment medication was reported.
Age: 80.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Vaccine was moved to refrigerator on 23-JUN-2023 and administered on 04-AUG-2023; no adverse event; Vaccine was administered beyond 30-day use.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine was administered beyond 30-day use.), PRODUCT STORAGE ERROR (Vaccine was moved to refrigerator on 23-JUN-2023 and administered on 04-AUG-2023) and NO ADVERSE EVENT (no adverse event) in an 80-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7643E) for COVID-19 prophylaxis.     No Medical History information was reported.    On 04-Aug-2023, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 04-Aug-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine was administered beyond 30-day use.) and NO ADVERSE EVENT (no adverse event). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine was moved to refrigerator on 23-JUN-2023 and administered on 04-AUG-2023). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine was administered beyond 30-day use.), PRODUCT STORAGE ERROR (Vaccine was moved to refrigerator on 23-JUN-2023 and administered on 04-AUG-2023) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Vaccine was administered beyond 30-day use.) and PRODUCT STORAGE ERROR (Vaccine was moved to refrigerator on 23-JUN-2023 and administered on 04-AUG-2023).    No concomitant medication was reported.  No treatment information was reported.
Age: 87.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Vaccine was pulled from freezer 06/23/23 and was stored in the refrigerator since; no adverse event; Expired vaccine was administered; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine was administered), PRODUCT STORAGE ERROR (Vaccine was pulled from freezer 06/23/23 and was stored in the refrigerator since) and NO ADVERSE EVENT (no adverse event) in an 87-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7643E) for COVID-19 prophylaxis.     No Medical History information was reported.    On 07-Aug-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 07-Aug-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine was administered). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine was pulled from freezer 06/23/23 and was stored in the refrigerator since) and NO ADVERSE EVENT (no adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine was administered), PRODUCT STORAGE ERROR (Vaccine was pulled from freezer 06/23/23 and was stored in the refrigerator since) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Expired vaccine was administered) and PRODUCT STORAGE ERROR (Vaccine was pulled from freezer 06/23/23 and was stored in the refrigerator since).    Concomitant medication details not reported by the reporter. Dosage text was reported as Unknown. Treatment details was not reported by the reporter.
Age: 63.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Vaccine was pulled from freezer 06/23/23 and was stored in the refrigerator since; no adverse event; Expired vaccine was administered.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine was administered.), PRODUCT STORAGE ERROR (Vaccine was pulled from freezer 06/23/23 and was stored in the refrigerator since) and NO ADVERSE EVENT (no adverse event) in a 63-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7643E) for COVID-19 prophylaxis.     No Medical History information was reported.    On 07-Aug-2023, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 07-Aug-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine was administered.). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine was pulled from freezer 06/23/23 and was stored in the refrigerator since) and NO ADVERSE EVENT (no adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine was administered.), PRODUCT STORAGE ERROR (Vaccine was pulled from freezer 06/23/23 and was stored in the refrigerator since) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Expired vaccine was administered.) and PRODUCT STORAGE ERROR (Vaccine was pulled from freezer 06/23/23 and was stored in the refrigerator since).    Concomitant medication details not reported by the reporter. Treatment details was not reported by the reporter.
Age: 50.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; Expired product administered; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired product administered) and NO ADVERSE EVENT (No adverse event) in a 6-decade-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 045H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 04-Aug-2023, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 04-Aug-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired product administered). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired product administered) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Expired product administered).    No concomitant medication was reported. It was reported that patient was in 50s.  No treatment medication was reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-736678 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-736678:female patient case
Age: 1.25
Sex: M
Vaccine: COVID19-2
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse event; 15 months old patient received a 0.2ml dose from a vial with a Dark Pink Cap and a Label with a Yellow Box as a second dose -instead of 0.25ml dose of the correct vial; This spontaneous case was reported by a physician and describes the occurrence of WRONG PRODUCT ADMINISTERED (15 months old patient received a 0.2ml dose from a vial with a Dark Pink Cap and a Label with a Yellow Box as a second dose -instead of 0.25ml dose of the correct vial) and NO ADVERSE EVENT (No adverse event) in a 15-month-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 214k22a) for COVID-19 prophylaxis.     Previously administered products included for COVID-19 prophylaxis: Moderna COVID19 vaccine (AS1417B First dose) on 04-Apr-2023. Past adverse reactions to the above products included No adverse event with Moderna COVID19 vaccine.    On 08-Aug-2023, the patient received second dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .2 milliliter. On 08-Aug-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced WRONG PRODUCT ADMINISTERED (15 months old patient received a 0.2ml dose from a vial with a Dark Pink Cap and a Label with a Yellow Box as a second dose -instead of 0.25ml dose of the correct vial). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (15 months old patient received a 0.2ml dose from a vial with a Dark Pink Cap and a Label with a Yellow Box as a second dose -instead of 0.25ml dose of the correct vial) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (15 months old patient received a 0.2ml dose from a vial with a Dark Pink Cap and a Label with a Yellow Box as a second dose -instead of 0.25ml dose of the correct vial).    No concomitant medication was reported.  No PQC was reported. No treatment information was reported.
Age: 64.0
Sex: F
Vaccine: COVID19-2
Symptoms: No adverse event, Poor quality product administered, Product temperature excursion issue
Clinical narrative: No adverse event; Dose have been administered to patient after this excursion occurred.; Moderna COVID-19 bivalent vaccine that were stored in the freezer that went out of range. The excursion occurred on 31JUL2023.; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna COVID-19 bivalent vaccine that were stored in the freezer that went out of range. The excursion occurred on 31JUL2023.), POOR QUALITY PRODUCT ADMINISTERED (Dose have been administered to patient after this excursion occurred.) and NO ADVERSE EVENT (No adverse event) in a 64-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7185B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 04-Aug-2023, the patient received third dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 31-Jul-2023, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna COVID-19 bivalent vaccine that were stored in the freezer that went out of range. The excursion occurred on 31JUL2023.). On 04-Aug-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Dose have been administered to patient after this excursion occurred.). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna COVID-19 bivalent vaccine that were stored in the freezer that went out of range. The excursion occurred on 31JUL2023.), POOR QUALITY PRODUCT ADMINISTERED (Dose have been administered to patient after this excursion occurred.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna COVID-19 bivalent vaccine that were stored in the freezer that went out of range. The excursion occurred on 31JUL2023.) and POOR QUALITY PRODUCT ADMINISTERED (Dose have been administered to patient after this excursion occurred.).    No concomitant medication was reported.  This patient could have potentially received dose from a vial that was stored in the refrigerator and did not experience any excursions, however HCP was not sure about that. AE was being reported for awareness. No treatment information was reported.  This case contains information for patient3 out of 3.   This case was linked to US-MODERNATX, INC.-MOD-2023-736986, US-MODERNATX, INC.-MOD-2023-736987 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-736986:Master case, Patient 1 US-MODERNATX, INC.-MOD-2023-736987:Patient 3